OCS-01 | OPTIMIZE Trial - Phase 3 Topline Results Treatment of pain and inflammation in post cataract surgery August 8, 2023 Rethinking Ophthalmology Exhibit 99.2

  These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements we make regarding the initiation, timing, progress and results of our preclinical studies, our clinical studies, our research and development programs, our regulatory strategy, our future development plans, our ability to advance product candidates into, and successfully complete, and the timing or likelihood of regulatory filings and approvals and statements regarding the potential therapeutic benefits and market opportunities of our product candidates are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. The clinical data presented herein is preliminary and is subject to change. These results may not be reproduced in subsequent patients and clinical trials. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the possibility that Oculis may be adversely affected by economic, business, and/or competitive factors; Oculis' estimates of expenses and profitability; Oculis' ability to develop, manufacture and commercialize the product candidates in its pipeline; actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; the ability of Oculis or its partners to enroll and retain patients in clinical studies; the ability of Oculis or its partners to gain approval from regulators for planned clinical studies, study plans or sites; Oculis' ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; the success of Oculis' current and future collaborations, joint ventures, partnerships or licensing arrangements; the ongoing and evolving COVID-19 pandemic on Oculis' business, financial position, strategy and anticipated milestones; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Oculis may from time to time file or furnish with the SEC. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.   Copyright of this presentation is owned by Oculis. No part of this presentation may be reproduced in any manner without the permission of Oculis. Disclaimers

Welcome to OPTIMIZE Trial Phase 3 Topline Results Opening Remarks Sylvia Cheung Chief Financial Officer OCS-01 Phase 3 OPTIMIZE Riad Sherif, M.D. Chief Executive Officer Q&A Session Eric Donnenfeld, M.D., Oculis SAB Michael Korenfeld , M.D., Principal Investigator, OPTIMIZE trial Riad Sherif, M.D., Chief Executive Officer Sylvia Cheung, Chief Financial Officer Concluding Remarks Riad Sherif, M.D. Chief Executive Officer Listing on NASDAQ DIAMOND Stage 1 Ph 3 Results R&D Retina Day OPTIMIZE Ph 3 Results Pipeline Overview $42M Gross Proceeds from Public Offering LEOPARD POC initiated Mar 3 Apr 13 May 22 June 2 July 11 Aug 2 Today

Key Opinion Leaders ERIC DONNENFELD, M.D. Dr. Donnenfeld is a trustee of Dartmouth Medical School and a clinical professor of ophthalmology at New York University. He is past president of American Society of Cataract and Refractive Surgery, president-elect of the International Intraocular Implant Society and is the editor-in-chief of EyeWorld. He has written over 200 peer review papers and 60 book chapters and books. He is a Fellow of the American Academy of Ophthalmology and has received its Lifetime Achievement Award. MICHAEL KORENFELD, M.D. Dr. Korenfeld founded and owns Comprehensive Eye Care, Ltd and he is an Assistant Clinical Professor at Washington University School of Medicine. Dr. Korenfeld is actively engaged in clinical research, having served as the Principal Investigator for over 140 FDA approved clinical trials in a variety of disciplines, such as glaucoma, dry eye, uveitis, post-cataract inflammation, intraocular lenses, capsular tension rings, and novel wound closure mechanisms.

OCS-01 in Phase 3 OPTIMIZE Trial Meets Both Primary Endpoints Highly significant reduction in pain and inflammation following cataract surgery in a consistent way with SKYGGN Trial (OCS-01 Ph2) Next Step: Second Phase 3 Trial Commence a second Phase 3 trial to support NDA submission of OCS-01 for the Treatment of Inflammation and Pain Following Ocular Surgery Primary Objective Achieved Results validated OCS-01 as a once-daily treatment for post-operative inflammation and pain following ocular surgery Met Both Primary Endpoints with Robust Statistical Significance Hierarchical Primary Endpoints: % patients inflammation free at Day 15: 57.2% with OCS-01 vs 24.0% with vehicle (p < 0.0001) % patients pain free at Day 4: 75.5% with OCS-01 vs 52.0% with vehicle (p < 0.0001) No unexpected safety findings

Ocular Surgery is the Most Common Surgical Intervention in the World1 Post-operative treatment regimen is required to mainly control pain and inflammation Cataract extractions are the most prevalent surgical procedure of all medical specialties1: aAnterior ocular procedures include cataract, MIGS, LASIK, DSAEK, PRK, PKP, DMEK and trabeculectomy. 1. Rossi T, et al., BMJ Open Ophthalmol. 2021; 13;6(1):e000464. 2. HCUPnet. 3. Meddevicetracker. 4. Data on file. Oculis Holding AG. 5. Ocular Surgery News. 2021. https://www.healio.com/news/ophthalmology/20210126/future-of-cataract-surgery-seems-promising. Estimated ocular procedures in the US2-4,a ~ 10M ~60,000 cataract surgeries are performed every day globally5 ~7M in 2022 by 2037 Global ~4M ~ 7M ~ 20M EU USA

Current Treatments for Post Ocular Surgery Complex regimens with potential complications, especially cystoid macular edema Current treatments include a combination of topical steroid, antibiotic and NSAID Up to 12 drops a day1 2-6 weeks treatment regimens CME: cystoid macular edema; IOP: intraocular pressure; NSAID=non-steroidal anti-inflammatory drugs ; OCT: Optical coherence tomography. 2. Burling-Phillips L. After Cataract Surgery: Watching for Cystoid Macular Edema. American Academy of Opthamology. 2007. https://www.aao.org/eyenet/article/after-cataract-surgery-watching-cystoid-macular-ed#:~:text=Insidious%20CME.,much%20remains%20unknown%20about%20it. 3. CRST Global. Prevention of CME After Cataract Surgery. 2013. https://crstodayeurope.com/articles/2013-julaug/prevention-of-cme-after-cataract-surgery. (Percentage applied to US; EU and world population). 4. Rossi T, et al., BMJ Open Ophthalmol. 2021; 13;6(1):e000464. 5. ARVO Annual Meeting Abstract, June 2021, Hennings et al. Prognostic determinants of postoperative pseudophakic macular oedema in a tertiary hospital setting. 6. Chu CJ, et.al. Ophthalmology. 2016:123:316-323. 7. Erikitola OO, et al. Eye. 2021;35:584–591. Regimen complexity often leads to low patient compliance and may result in suboptimal treatment outcomes CME is the most significant cause of decreased vision in patients following cataract surgery2 Clinically significant CME occurs in up to 5.8% of cataract surgeries3 representing ~215K cases in the US, ~400K cases in EU, and 1.6M cases worldwide3,4 In 30% of the patients defined as high-risk due to pre-existing conditions (e.g., diabetes, uveitis)5-7, the risk of clinically significant CME following ocular surgery may increase to 56%5 There are no approved treatments or prevention for post-surgery CME

With the potential to address multiple indications Unique product candidate with clinically validated MOA OCS-01: High-concentration Optireach® formulation of dexamethasone (15mg/ml) OPTIREACH® Formulation Technology Longer residence time enables once daily administration in post ocular surgery1 BCVA: best corrected visual acuity; CME: cystoid macular edema; CST: central subfield thickness; DME: diabetic macular edema. aEffect of OCS-01 was sustained through Week 12. 1. Korenfeld M,et al. Clin Ther. 2022;44(12):1577-1587. 2. Oculis announces positive top line results from DIAMOND Stage 1 phase 3 trial in diabetic macular edema with OCS-01 eye drops. .May 22, 2023. 3. Shulman S, et al. Acta Ophthalmol. 2015;93(5):411-415. OCS-01 – First Eye Drop Designed for Front and Back of the Eye 2/ DME Ph3 Stage 1 Diamond Trial : OCS-01 Met Primary Endpoints2 Active Arm vs vehicle (N=148) at Week 6a Mean Change BCVA +7.2 letters vs +3.1% (P=0.007) % with ≥ 3-line gain in BCVA 25.3% vs 9.8% (P=0.015) Mean Change in CST -63.6 μm vs +5.5 μm (P < 0.0001) 3/ CME Pilot study supports OCS-01 treatment potential OCS-01 demonstrated improvement in retinal edema / CME3 Addresses critical unmet medical need for high-risk patients undergoing ocular surgery 1/ Ocular Surgery Ph2 SKYGGN Trial: OCS-01 Once-daily Met Primary Endpoints1 Active Arm vs vehicle (N=153) ZERO INFLAMMATION (Day 15) 51.0% vs 19.6% (P=0.0009) ZERO PAIN (Day 4) 72.5% vs 45.1% (P=0.0049) OCS-013

OPTIMIZE Phase 3 Trial Results

OPTIMIZE Trial Evaluated OCS-01 for Treatment of Inflammation and Pain Following Cataract Surgery A multi-center, randomized, double-masked, vehicle-controlled, phase 3 trial of OCS-01 (OPTIREACH®-dexamethasone 15 mg/mL ophthalmic formulation) ACC: anterior chamber cells; AE:adverse event; ETDRS: Early Treatment Diabetic Retinopathy Study; IOP: intraocular pressure; PCIOL: posterior chamber intraocular lense; QD: once daily; VA: visual acuity. Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing. 2 Weeks OCS-01 1x/day (QD) Screening and Baseline evaluations (prior to surgery) Vehicle 1x/day (QD) Key Inclusion Criteria Age ≥18 years Planned unilateral cataract extraction using phacoemulsification and PCIOL implantation ACC score ≥ 2 at Visit 2 (Day 1, 18–30 hours post-uncomplicated surgery) Pin-hole VA > 20 letters (20/400) in study eye and > 35 letters (20/200) in fellow eye using ETDRS at Visit 1 Endpoints Hierarchical Primary Efficacy Measures: Absence of anterior chamber cells (i.e. score of ‘0’) at Visit 6 (Day 15) Absence of pain (i.e. score of ‘0’) at Visit 4 (Day 4) Safety Measures: IOP, Endothelial Cell Density and AEs End of treatment Off Treatment 2.5 Months Safety assessments and Endothelial Cell Density Safety assessments and endothelial cell density Surgery day and Randomization 1:1 Drug administration started on Day 1 after cataract surgery N = 241

OPTIMIZE Patient Disposition AE: adverse event. Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing. OCS-01 n = 119 Vehicle n = 122 Completed 15 weeks n = 116 Completed 15 weeks n = 118 Discontinued study Withdrawn: n = 1 AE: n = 1 Other: n = 2 Discontinued study Withdrawn: n = 2 Other: n = 1 Randomized n = 241 Full Analysis Set Per Protocol Safety Population 241 214 241

Baseline Demographics Full analysis set Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing. Parameter OCS-01 (n = 119) Vehicle (n = 122) Mean age, years (SD) 68.8 (7.8) 67.8 (9.0) Age < 65 years, n (%) 24 (20.2) 30 (24.6) Age ≥ 65 years, n (%) 95 ( 79.8) 92 ( 75.4) Male, n (%) 48 ( 40.3) 52 ( 42.6) Race, n (%) White 95 (79.8) 91 (74.6) Black or African American 17 (14.3) 25 (20.5) Asian 6 (5.0) 5 (4.1) American Indian or Alaska Native 1 (0.8) 0 (0.0) Other 0 (0.0) 1 (0.8) Iris color in the study eye, n (%) Brown 70 ( 58.8) 76 ( 62.3) Blue 22 ( 18.5) 29 ( 23.8) Hazel 20 ( 16.8) 12 ( 9.8) Green 4 ( 3.4) 4 ( 3.3) Gray 2 ( 1.7) 1 ( 0.8) Black 1 ( 0.8) 0 (0.0)

Efficacy

Primary Endpoint: Absence of Anterior Chamber Cells on Day 15 Primary analysis, full analysis set P < 0.0001 ACC: anterior chamber cells. Data for visits after receipt of rescue medication, or missing data resulting from withdrawal due to adverse event or lack of efficacy, are singly imputed as failure. Missing data without withdrawal or resulting from withdrawal due to reasons other than adverse event or lack of efficacy are multiply imputed using treatment-based Markov Chain Monte Carlo methodology. Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing.

Primary endpoint Secondary endpoints Proportion of Patients With Absence of Anterior Chamber Cells by Visit Full analysis set ACC: anterior chamber cells. Secondary endpoints contain observed data only. Missing data for the primary endpoint are imputed. Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing. P < 0.0001

Primary Endpoint: Absence of Ocular Pain on Day 4 Primary analysis, full analysis set P < 0.0001 Data for visits after receipt of rescue medication, or missing data resulting from withdrawal due to adverse event or lack of efficacy, are singly imputed as failure. Missing data without withdrawal or resulting from withdrawal due to reasons other than adverse event or lack of efficacy are multiply imputed using treatment-based Markov Chain Monte Carlo methodology. Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing.

Primary endpoint Secondary endpoint Secondary endpoints Proportion of Patients With Absence of Ocular Pain by Visit Full analysis set Secondary endpoints contain observed data only. Missing data for the primary endpoint are imputed. Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing. P < 0.0001

Safety

Overall Summary of Treatment-Emergent Adverse Events Safety population COVID-19: coronavirus disease 2019; TEAE: treatment-emergent adverse event; TE-SAE: treatment-emergent serious adverse event. Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing. OCS-01 (n = 119) Vehicle (n = 122) Events Patients, n (%) Events Patients, n (%) Any TEAE 60 35 (29.4) 102 45 (36.9) Any non-ocular TEAE 14 12 (10.1) 7 6 (4.9) Any ocular TEAE in the study eye 37 24 (20.2) 84 41 (33.6) Maximum severity of ocular TEAEs in the study eye Mild 14 (11.8) 21 (17.2) Moderate 9 (7.6) 19 (15.6) Severe 1 (0.8) 1 (0.8) Suspected treatment-related ocular TEAEs in the study eye 8 5 (4.2) 14 9 (7.4) Ocular TEAEs in the study eye leading to study drug discontinuation 3 (2.5) 10 (8.2) Any TE-SAE 0 0 1 1 (0.8) COVID-19 0 0 1 1 (0.8)

Ocular Treatment-Emergent Adverse Events in the Study Eye (> 2.0% in the OCS-01 Arm or in the Vehicle Arm) Safety population TEAE: treatment-emergent adverse event. Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing. OCS-01 (n = 119) Vehicle (n = 122) Events Patients, n (%) Events Patients, n (%) Any ocular TEAE in the study eye 37 24 (20.2) 84 41 (33.6) Anterior chamber inflammation 5 5 (4.2) 4 4 (3.3) Eye inflammation 4 4 (3.4) 6 6 (4.9) Cystoid macular edema 3 3 (2.5) 5 5 (4.1) Corneal edema 2 2 (1.7) 6 6 (4.9) Eye pain 2 2 (1.7) 8 8 (6.6) Posterior capsule opacification 2 2 (1.7) 6 6 (4.9) Conjunctival hyperemia 2 2 (1.7) 5 5 (4.1) Iritis 1 1 (0.8) 6 6 (4.9) Photophobia 1 1 (0.8) 4 4 (3.3) Ocular hyperaemia 0 0 (0.0) 3 3 (2.5)

Pre-treatment/ surgery Mean IOP in Study Eyes by Visit Safety population BL: baseline; IOP: intraocular pressure. Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing.

Pre-treatment/ surgery Endothelial Cell Density in Study Eyes by Visit Safety population BL: baseline. Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing.

Summary

OCS-01 Efficacy and Safety Summary Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing. OCS-01 has met the primary endpoints in OPTIMIZE Phase 3 trial, showing superiority over placebo for treatment of inflammation and pain following cataract surgery No unexpected safety findings observed Inflammation : Improve absence of anterior chamber cells (Primary Endpoint) 57.2% with OCS-01 vs 24.0% with vehicle (p < 0.0001) Pain: Improve absence of ocular pain (Primary Endpoint) 75.5% with OCS-01 vs 52.0% with vehicle (p < 0.0001) Next Step Commence a second Phase 3 trial to support NDA submission of OCS-01 for the Treatment of Inflammation and Pain Following Ocular Surgery

Source Dosing ZERO INFLAMMATION (Day 15) % Drug vs vehicle PAIN FREE (Day 4) % Drug vs vehicle OCS-01 Active Arm P value Active Arm P value OCS-01 SKYGGN Phase 2 Trial 1x/day 51.0% vs 19.6% P = 0.0009 72.5% vs 45.1% P = 0.0049 OCS-01 OPTIMIZE Phase 3 Trial 1x/day 57.2% vs 24.0% P < 0.0001 75.5% vs 52.0% P < 0.0001 Consistent Results With OCS-01 in OPTIMIZE & SKYGGN Trials Topline Efficacy Summary with Once Daily OCS-01 in Phase 2 and Phase 3

Phase 3 trial results & Prescribing Information1-4,a Loteprednol 1% 2x/day 50% vs 27% +23% Day 4: 43% vs 25% +18% Difluprednate 0.05% 4x/day 41% vs 12% +29% Day 8: 58% vs 27% +21% Loteprednol 0.38% 3x/day 47% vs 25% +22% Day 8: 74% vs 49% +25% OCS-01 Ph 3 and Ph 2 Results Compared to Current Standard of Care Topline efficacy summary with comparators with pain and inflammation labela aNo head to head studies. 1. INVELTYS Prescribing Information. Kala Pharmaceuticals. 2022. 2. DUREZOL Prescribing Information. Novartis. 2020. 3. LOTEMAX SM Prescribing Information. B&L. 2023. 4. Fong R, et al., Clin Ophthalmol. 2019;13:1427-1438 Source Active Ingredient Dosing ZERO INFLAMMATION (Day 15) % Drug vs vehicle PAIN FREE (Day 4) % Drug vs vehicle OCS-01 Phase 2&3 trials Dexamethasone 1.5%   1x/day Phase 3 Phase 2 Active Arm Delta vs vehicle Active Arm Delta vs vehicle 57% vs 24% +33% Day 4: 75% vs 52% +23% 51% vs 20% +31% Day 4: 73% vs 45% +28% Phase 3 57% vs 24% +33% Day 4: 75% vs 52% +23%

Benefits highlighted in independent third-party market research studies with payers & physicians1,2 Ophthalmologists Ocular Surgery Patients Payors Once daily has potential to improve compliance and therefore patient outcomes Positive results in reduction of both pain and inflammation in a once daily dosing regimen OCS-01 also in development for back-of-the-eye / retina indications Once daily eye drops Preservative free OCS-01 Could Offer potential value to all stakeholders Clearview market research, OCS-01 Surgical Inflammation U.S. Opportunity Assessment 2020 Akceso Advisors AG, OCS-01 Post Ocular Inflammation and Pain, Payers and Clinical Expert Research 2020

OCS-01 Total Addressable Market Potential $3.9B Current DME Market1 +$5.2B Potential DME Market1 Diagnosed & Untreated $922M US Ocular Steroids4 +$762M Potential CME Market5 +$753M Uveitis3 +$2.3B RVO2 ~$10B+ Potential Market Opportunity Addressable Market Size USD Bn ~$4.7B Diabetic Macular Edema (DME)1 Post Ocular Surgery2 ~$5.8B DME diagnosed & untreated3 Cystoid Macular Edema (CME)4 ~$3.1B Retinal Vein Occlusion5 Uveitis6 Core indications New market opportunities Potential future life cycle Management DR and DME Disease and Landscape report Nov. 2020 – 2023 market value estimate for DME (not DR) in G7, $3.9Bn IQVIA 2019 Ex-factory Sales for Ocular Steroids (without Ozurdex & Iluvien sales) for US and EU5, $0.8Bn DR and DME Disease and Landscape report Nov. 2020 – 2023 market value estimate for G7, Diagnosed untreated patient proportion with ratio applied to current sales (43% treated, 57% untreated). $5.2Bn Estimated CME market potential based on 1.5 injections of Ozurdex per patient * 2.3% Clinically significant CME incidence following cataract surgery * 11M Cataract surgery / year for US & EU. $0.6Bn Global RVO Estimated Market Value - https://www.futuremarketinsights.com/reports/retinal-vein-occlusion-treatment-market. $2.3Bn GlobalData – Opportunity Analysis and Forecasts November 2017 – Estimated global sales in G7 in 2023. $0.8Bn

AMD; age-related macular degeneration; DR: diabetic retinopathy ; RVO: retinal vein occlusion. OCS-01 is based on the OPTIREACH® technology, OCS-02 is a single chain antibody fragment (ScFv) against TNFα and OCS-05 is a SGK-2 activator peptidomimetic small molecule with novel MoA targeting the activation of the trophic factor pathways. Product Candidate(s) Investigational Indication(s) Pre-clinical Phase 1 Phase 2 Phase 3 OCS-01 Optireach® technology OCS-02 Anti TNF OCS-05 SGK2 Activator OCS-03 (Undisclosed) DIABETIC MACULAR EDEMA INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY DRY EYE DISEASE UVEITIS ACUTE OPTIC NEURITIS GLAUCOMA DIABETIC RETINOPATHY CORNEAL NV, PTERYGIUM Wet-AMD, RVO, DR GEOGRAPHIC ATROPHY OCS-04 CORNEAL TRANSPLANT CYSTOID MACULAR EDEMA Innovative, Diversified and Late-stage Pipeline 2023 2024 1⁰ endpt. met Ph3 NDA PoC readout Ph2b readout Ph2b readout PoC readout Next Catalysts NEUROTROPHIC KERATITIS 1⁰ endpt. met Stage 1 Ph3

Uniquely Positioned to Build Significant Value Targeting critical unmet needs in major ophthalmology segments Near-term value inflection points expected AON: acute optic neuritis ;CME: cystoid macular edema. OCS-01: 1st Eye drop for Diabetic Macular Edema (DME) in Ph3 OCS-01: 1st Once a day Eye drop for ocular surgery Inflammation & Pain in Ph3 OCS-02: 1st Biologic eye drop for Dry Eye Disease (DED) in Ph2b (upside potential from biomarker-driven precision medicine approach) OCS-05: 1st Neuroprotective agent for neuro-retina treatments in PoC 2023 2024 OCS-01 DME Phase 3 (Stage 1) topline readout OCS-01 Ocular Surgery Phase 3 topline readout OCS-01 Ocular Surgery NDA OCS-01 CME PoC readout OCS-02 DED Phase 2b readout OCS-02 Uveitis Phase 2b readout OCS-05 AON PoC readout

To drive innovation to save sight and improve eye care Our Purpose

Q&A Session

Q&A Panel Riad Sherif, M.D. Sylvia Cheung Eric Donnenfeld, M.D. Michael Korenfeld, M.D. CEO, Oculis CFO, Oculis Oculis Scientific Advisory Board Principal Investigator